• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Monday, November 3, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Biology

Resolution time of COVID vaccine-related lymphadenopathy

Bioengineer by Bioengineer
May 20, 2022
in Biology
Reading Time: 2 mins read
0
Lymph node measurements in 33-year-old woman for bilateral screening breast ultrasound
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Leesburg, VA, May 19, 2022—According to ARRS’ American Journal of Roentgenology (AJR), axillary lymphadenopathy detected by breast ultrasound after COVID-19 mRNA vaccination lasts longer than reported in initial vaccine clinical trials.

Lymph node measurements in 33-year-old woman for bilateral screening breast ultrasound

Credit: American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR

Leesburg, VA, May 19, 2022—According to ARRS’ American Journal of Roentgenology (AJR), axillary lymphadenopathy detected by breast ultrasound after COVID-19 mRNA vaccination lasts longer than reported in initial vaccine clinical trials.

“The prolonged resolution time supports a follow-up interval of at least 12 weeks for suspected vaccine-related lymphadenopathy and avoidance of delaying screening mammography after vaccination,” wrote corresponding author Michele B. Drotman, MD.

Drotman and the Weill Cornell Medicine team extracted health record data for 111 patients (mean age, 52 years) with unilateral axillary lymphadenopathy ipsilateral to administration of Pfizer or Moderna COVID-19 vaccine—performed within 8 weeks prior and detected on breast ultrasound (January 1–October 1, 2021) that underwent follow-up ultrasound examinations at 4–12 weeks.

In this single-center study, axillary lymphadenopathy ipsilateral to COVID-19 mRNA vaccination resolved after a mean of 97 days since detection by breast imaging and 127 days since the first dose. Longer times to resolution were observed with Moderna (rather than Pfizer) vaccination, receipt of second dose after presentation, and thicker cortical thickness at presentation.

“The presence of subclinical lymphadenopathy and the long resolution time of lymphadenopathy,” the authors of this AJR article noted, “should reassure radiologists and patients when lymph nodes suspected to be vaccine-related persist over multiple visits.”


North America’s first radiological society, the American Roentgen Ray Society (ARRS) remains dedicated to the advancement of medicine through the profession of medical imaging and its allied sciences. An international forum for progress in radiology since the discovery of the x-ray, ARRS maintains its mission of improving health through a community committed to advancing knowledge and skills with the world’s longest continuously published radiology journal—American Journal of Roentgenology—the ARRS Annual Meeting, InPractice magazine, topical symposia, myriad multimedia educational materials, as well as awarding scholarships via The Roentgen Fund®.



Journal

American Journal of Roentgenology

DOI

10.2214/AJR.22.27687

Method of Research

Observational study

Subject of Research

People

Article Title

Time for resolution of COVID-19 vaccine-related lymphadenopathy and associated factors

COI Statement

N/A

Share12Tweet8Share2ShareShareShare2

Related Posts

blank

Scientists Discover New Switch That Triggers Programmed Cell Death

November 3, 2025
blank

Agricultural Practices: A Key Factor in the Preservation or Degradation of Protected Areas

November 3, 2025

Phylogenomics Merges Mameliella and Maliponia into Antarctobacter

November 2, 2025

Overcoming Batch Effects in Single-Cell RNA-seq Datasets

November 2, 2025

POPULAR NEWS

  • Sperm MicroRNAs: Crucial Mediators of Paternal Exercise Capacity Transmission

    1296 shares
    Share 518 Tweet 324
  • Stinkbug Leg Organ Hosts Symbiotic Fungi That Protect Eggs from Parasitic Wasps

    312 shares
    Share 125 Tweet 78
  • ESMO 2025: mRNA COVID Vaccines Enhance Efficacy of Cancer Immunotherapy

    204 shares
    Share 82 Tweet 51
  • New Study Suggests ALS and MS May Stem from Common Environmental Factor

    137 shares
    Share 55 Tweet 34

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Enhanced Asymmetric Supercapacitor via Ni-Doped MnMoO4 & CNTs

Enhancing Adolescent Health Literacy: Insights from Nurses

CoMn2O4-rGO Nanocomposite Enhances Supercapacitor Performance

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 67 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.